Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314290 | 0.85 | KMT2A (0.47) | RXFP1NPSR1KMT2ATP53MAPT | |
| SCHEMBL1060995 | 0.83 | RXFP1 (0.42) | RXFP1NPSR1KMT2APOLBMITF | |
| SCHEMBL12932764 | 0.82 | RXFP1 (0.41) | RXFP1NPSR1KMT2APOLBMITF | |
| SCHEMBL1062384 | 0.82 | ADORA2B (0.42) | RXFP1NPSR1KMT2APOLBMITF | |
| SCHEMBL10314315 | 0.82 | PGR (0.42) | RXFP1NPSR1KMT2APOLBMITF | |
| SCHEMBL10314203 | 0.81 | SMN1; SMN2 (0.43) | RXFP1NPSR1KMT2AMITFMEN1 | |
| Trifluoroacetic Acid SCHEMBL1063966 | 0.81 | KMT2A (0.43) | RXFP1NPSR1KMT2APOLBTP53 | |
| Hydrochloric Acid SCHEMBL1064006 | 0.81 | SMN1; SMN2 (0.43) | RXFP1NPSR1KMT2AMITFMEN1 | |
| SCHEMBL1063589 | 0.80 | SMN1; SMN2 (0.41) | RXFP1NPSR1KMT2AMITFMEN1 | |
| SCHEMBL1057152 | 0.80 | RXFP1 (0.39) | RXFP1NPSR1KMT2APOLBMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399449-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | RXFP1 277/4885NPSR1 423/4885KMT2A 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.